We provide you with 20 years of free, institutional-grade data for SUPN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SUPN. Explore the full financial landscape of SUPN stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-05 | 1356576 | SUPN | 10-Q | Url |
| 2025-05-06 | 1356576 | SUPN | 10-Q | Url |
| 2025-02-25 | 1356576 | SUPN | 10-K | Url |
| 2024-11-04 | 1356576 | SUPN | 10-Q | Url |
| 2024-08-06 | 1356576 | SUPN | 10-Q | Url |
| 2024-05-08 | 1356576 | SUPN | 10-Q | Url |
| 2024-02-27 | 1356576 | SUPN | 10-K | Url |
| 2023-11-08 | 1356576 | SUPN | 10-Q | Url |
| 2023-08-08 | 1356576 | SUPN | 10-Q | Url |
| 2023-05-09 | 1356576 | SUPN | 10-Q | Url |
| 2023-03-09 | 1356576 | SUPN | 10-K | Url |
| 2022-11-09 | 1356576 | SUPN | 10-Q | Url |
| 2022-08-08 | 1356576 | SUPN | 10-Q | Url |
| 2022-05-12 | 1356576 | SUPN | 10-Q | Url |
| 2022-04-13 | 1356576 | SUPN | 10-K | Url |
| 2021-11-05 | 1356576 | SUPN | 10-Q | Url |
| 2021-08-06 | 1356576 | SUPN | 10-Q | Url |
| 2021-05-07 | 1356576 | SUPN | 10-Q | Url |
| 2021-03-08 | 1356576 | SUPN | 10-K | Url |
| 2020-11-06 | 1356576 | SUPN | 10-Q | Url |
| 2020-08-17 | 1356576 | SUPN | 10-Q | Url |
| 2020-05-15 | 1356576 | SUPN | 10-Q | Url |
| 2020-02-28 | 1356576 | SUPN | 10-K | Url |
| 2019-11-08 | 1356576 | SUPN | 10-Q | Url |
| 2019-08-09 | 1356576 | SUPN | 10-Q | Url |
| 2019-05-10 | 1356576 | SUPN | 10-Q | Url |
| 2019-03-01 | 1356576 | SUPN | 10-K | Url |
| 2018-11-09 | 1356576 | SUPN | 10-Q | Url |
| 2018-08-09 | 1356576 | SUPN | 10-Q | Url |
| 2018-05-10 | 1356576 | SUPN | 10-Q | Url |
| 2018-03-01 | 1356576 | SUPN | 10-K | Url |
| 2017-11-09 | 1356576 | SUPN | 10-Q | Url |
| 2017-08-03 | 1356576 | SUPN | 10-Q | Url |
| 2017-05-09 | 1356576 | SUPN | 10-Q | Url |
| 2017-03-16 | 1356576 | SUPN | 10-K | Url |
| 2017-01-20 | 1356576 | SUPN | 10-Q | Url |
| 2016-08-05 | 1356576 | SUPN | 10-Q | Url |
| 2016-05-10 | 1356576 | SUPN | 10-Q | Url |
| 2016-03-09 | 1356576 | SUPN | 10-K | Url |
| 2015-11-09 | 1356576 | SUPN | 10-Q | Url |
| 2015-08-07 | 1356576 | SUPN | 10-Q | Url |
| 2015-05-06 | 1356576 | SUPN | 10-Q | Url |
| 2015-03-12 | 1356576 | SUPN | 10-K | Url |
| 2014-11-12 | 1356576 | SUPN | 10-Q | Url |
| 2014-08-12 | 1356576 | SUPN | 10-Q | Url |
| 2014-05-13 | 1356576 | SUPN | 10-Q | Url |
| 2014-03-21 | 1356576 | SUPN | 10-K | Url |
| 2013-11-13 | 1356576 | SUPN | 10-Q | Url |
| 2013-08-14 | 1356576 | SUPN | 10-Q | Url |
| 2013-05-15 | 1356576 | SUPN | 10-Q | Url |
| 2013-03-15 | 1356576 | SUPN | 10-K | Url |
| 2012-11-14 | 1356576 | SUPN | S-1 | Url |
| 2012-11-02 | 1356576 | SUPN | 10-Q | Url |
| 2012-08-13 | 1356576 | SUPN | 10-Q | Url |
| 2012-06-08 | 1356576 | SUPN | 10-Q | Url |
| 2010-12-23 | 1356576 | SUPN | S-1 | Url |
Supernus Pharmaceuticals, Inc(NASDAQ:SUPN) 
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the t...
Website: http://www.supernus.com
Founded: 2005
Full Time Employees: 464
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
The information provided in this report about SUPN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.